ZURICH Novartis AG has announced that it will ask the U.S. Supreme Court to confirm the validity of a patent on the multiple sclerosis drug Gilenya. The decision was made after a setback in a Federal Appeals Court ruling.
It said that HEC Pharma and other drugmakers could launch a generic version 0.5 mg Gilenya as soon as possible, subject to any other judicial actions.
Related: Swiss officials are looking into how Novartis used its patents.
“Should generics be launched in the US, we anticipate FY 2022 sales being negatively affected by USD 0.3bn. It also stated that 2022 Full-Year Guidance for Group Sales and Core Operating Income Growth is expected to remain in the low single digits, in constant currencies.